These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 20933304)

  • 1. Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.
    Carr M; Greene LM; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
    Eur J Med Chem; 2010 Dec; 45(12):5752-66. PubMed ID: 20933304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents.
    O'Boyle NM; Carr M; Greene LM; Bergin O; Nathwani SM; McCabe T; Lloyd DG; Zisterer DM; Meegan MJ
    J Med Chem; 2010 Dec; 53(24):8569-84. PubMed ID: 21080725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects.
    Barrett I; Carr M; O'Boyle N; Greene LM; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
    J Enzyme Inhib Med Chem; 2010 Apr; 25(2):180-94. PubMed ID: 20222762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin.
    Odlo K; Hentzen J; dit Chabert JF; Ducki S; Gani OA; Sylte I; Skrede M; Flørenes VA; Hansen TV
    Bioorg Med Chem; 2008 May; 16(9):4829-38. PubMed ID: 18396050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral β-lactam bridged combretastatin A-4 analogues as potent antitumor agents.
    Zhou P; Liang Y; Zhang H; Jiang H; Feng K; Xu P; Wang J; Wang X; Ding K; Luo C; Liu M; Wang Y
    Eur J Med Chem; 2018 Jan; 144():817-842. PubMed ID: 29306206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents.
    Chang JY; Yang MF; Chang CY; Chen CM; Kuo CC; Liou JP
    J Med Chem; 2006 Oct; 49(21):6412-5. PubMed ID: 17034147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues.
    Theeramunkong S; Caldarelli A; Massarotti A; Aprile S; Caprioglio D; Zaninetti R; Teruggi A; Pirali T; Grosa G; Tron GC; Genazzani AA
    J Med Chem; 2011 Jul; 54(14):4977-86. PubMed ID: 21696175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further naphthylcombretastatins. An investigation on the role of the naphthalene moiety.
    Maya AB; Pérez-Melero C; Mateo C; Alonso D; Fernández JL; Gajate C; Mollinedo F; Peláez R; Caballero E; Medarde M
    J Med Chem; 2005 Jan; 48(2):556-68. PubMed ID: 15658869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.
    Greene LM; Nathwani SM; Bright SA; Fayne D; Croke A; Gagliardi M; McElligott AM; O'Connor L; Carr M; Keely NO; O'Boyle NM; Carroll P; Sarkadi B; Conneally E; Lloyd DG; Lawler M; Meegan MJ; Zisterer DM
    J Pharmacol Exp Ther; 2010 Nov; 335(2):302-13. PubMed ID: 20699436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of thiophene analogues of chalcones.
    Romagnoli R; Baraldi PG; Carrion MD; Cara CL; Cruz-Lopez O; Preti D; Tolomeo M; Grimaudo S; Di Cristina A; Zonta N; Balzarini J; Brancale A; Sarkar T; Hamel E
    Bioorg Med Chem; 2008 May; 16(10):5367-76. PubMed ID: 18440234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents.
    Liou JP; Chang YL; Kuo FM; Chang CW; Tseng HY; Wang CC; Yang YN; Chang JY; Lee SJ; Hsieh HP
    J Med Chem; 2004 Aug; 47(17):4247-57. PubMed ID: 15293996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones.
    O'Boyle NM; Greene LM; Bergin O; Fichet JB; McCabe T; Lloyd DG; Zisterer DM; Meegan MJ
    Bioorg Med Chem; 2011 Apr; 19(7):2306-25. PubMed ID: 21397510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41.
    Pettit GR; Rhodes MR; Herald DL; Hamel E; Schmidt JM; Pettit RK
    J Med Chem; 2005 Jun; 48(12):4087-99. PubMed ID: 15943482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design.
    Sun L; Vasilevich NI; Fuselier JA; Hocart SJ; Coy DH
    Bioorg Med Chem Lett; 2004 May; 14(9):2041-6. PubMed ID: 15080975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells.
    Malebari AM; Fayne D; Nathwani SM; O'Connell F; Noorani S; Twamley B; O'Boyle NM; O'Sullivan J; Zisterer DM; Meegan MJ
    Eur J Med Chem; 2020 Mar; 189():112050. PubMed ID: 31954879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of novel combretastatin A-4 thio derivatives as microtubule targeting agents.
    Stefański T; Mikstacka R; Kurczab R; Dutkiewicz Z; Kucińska M; Murias M; Zielińska-Przyjemska M; Cichocki M; Teubert A; Kaczmarek M; Hogendorf A; Sobiak S
    Eur J Med Chem; 2018 Jan; 144():797-816. PubMed ID: 29291446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting β-lactam combretastatins.
    O'Boyle NM; Greene LM; Keely NO; Wang S; Cotter TS; Zisterer DM; Meegan MJ
    Eur J Med Chem; 2013 Apr; 62():705-21. PubMed ID: 23454513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro.
    Nathwani SM; Hughes L; Greene LM; Carr M; O'Boyle NM; McDonnell S; Meegan MJ; Zisterer DM
    Oncol Rep; 2013 Feb; 29(2):585-94. PubMed ID: 23232969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity.
    Simoni D; Romagnoli R; Baruchello R; Rondanin R; Grisolia G; Eleopra M; Rizzi M; Tolomeo M; Giannini G; Alloatti D; Castorina M; Marcellini M; Pisano C
    J Med Chem; 2008 Oct; 51(19):6211-5. PubMed ID: 18783207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins.
    Bailly C; Bal C; Barbier P; Combes S; Finet JP; Hildebrand MP; Peyrot V; Wattez N
    J Med Chem; 2003 Dec; 46(25):5437-44. PubMed ID: 14640552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.